验证达拉斯脂肪变性指数在英国生物库人群中预测非酒精性脂肪性肝病的价值。
Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population.
机构信息
Division of Gastroenterology, Department of Medicine, Washington University in Saint Louis, St. Louis, Missouri.
Division of Public Health Sciences, Department of Surgery, Washington University in Saint Louis, St. Louis, Missouri.
出版信息
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2638-2640. doi: 10.1016/j.cgh.2021.05.035. Epub 2021 May 25.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a global public health crisis that affects one quarter of the world population. Preventing either cardiometabolic or liver-related complications by achieving weight loss and resolving hepatic steatosis would be the central goal of a NAFLD screening program in the primary care setting. Despite the overwhelming prevalence and the multimodal impact on health posed by NAFLD, specialty society guidelines do not recommend screening for NAFLD in the general population, partly owing to the as-yet unproven cost benefit.
摘要
非酒精性脂肪性肝病（NAFLD）是一个全球性的公共健康危机，影响着全球四分之一的人口。通过减轻体重和消除肝脂肪变性来预防与代谢或肝脏相关的并发症，这将是初级保健环境中 NAFLD 筛查计划的核心目标。尽管 NAFLD 的患病率极高，对健康的影响也多种多样，但专业学会指南并未建议在一般人群中筛查 NAFLD，部分原因是其成本效益尚未得到证实。
相似文献
1
Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population.验证达拉斯脂肪变性指数在英国生物库人群中预测非酒精性脂肪性肝病的价值。
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2638-2640. doi: 10.1016/j.cgh.2021.05.035. Epub 2021 May 25.
2
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.胰岛素增敏剂治疗非酒精性脂肪性肝病：系统评价。
Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380.
3
Zeroing in on Hepatic Steatosis Screening in Patients with Type 2 Diabetes Mellitus: A Retrospective Analysis of the Vicious Trifecta-Obesity, Nonalcoholic Fatty Liver Disease, and Diabetes.聚焦2型糖尿病患者的肝脂肪变性筛查：肥胖、非酒精性脂肪性肝病和糖尿病“邪恶三联征”的回顾性分析
J Assoc Physicians India. 2025 May;73(5):14-18. doi: 10.59556/japi.73.0956.
4
The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden.1990年至2021年非酒精性脂肪性肝病（包括肝硬化）对老年人的全球影响及疾病负担的未来预测。
PLoS One. 2025 Jun 25;20(6):e0325961. doi: 10.1371/journal.pone.0325961. eCollection 2025.
5
The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.非酒精性肝病患者小肠细菌过度生长的患病率：NAFLD、NASH、纤维化、肝硬化-系统评价、荟萃分析和荟萃回归。
Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261.
6
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.非酒精性脂肪性肝病的营养补充：一项网状Meta分析。
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013157. doi: 10.1002/14651858.CD013157.pub2.
7
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.非酒精性脂肪性肝病（NAFLD）的药物干预：一项网状Meta分析尝试
Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2.
8
Association between metabolic-associated fatty liver disease and risk of cardiometabolic multimorbidity: a disease trajectory analysis in UK Biobank.代谢相关脂肪性肝病与心脏代谢多重疾病风险之间的关联：英国生物银行的疾病轨迹分析
Front Endocrinol (Lausanne). 2025 Jun 18;16:1585725. doi: 10.3389/fendo.2025.1585725. eCollection 2025.
9
Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.非酒精性脂肪性肝病的生活方式干预：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Jun 11;6(6):CD013156. doi: 10.1002/14651858.CD013156.pub2.
10
Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.植物疗法作为一种多靶点治疗方法应对非酒精性脂肪性肝病的多种病理生理学：实验干预的系统评价。
Medicina (Kaunas). 2021 Aug 14;57(8):822. doi: 10.3390/medicina57080822.
引用本文的文献
1
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.甘油三酯-血糖-腰围指数：代谢功能障碍相关脂肪性肝病的有力工具。
World J Hepatol. 2025 Jul 27;17(7):107668. doi: 10.4254/wjh.v17.i7.107668.
2
The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.达拉斯脂肪变性指数在亚洲人群中的外部验证：一种用于识别和预防代谢功能障碍相关脂肪性肝病的有用工具。
J Gastroenterol. 2025 May;60(5):621-631. doi: 10.1007/s00535-025-02220-4. Epub 2025 Feb 24.
3
Night shift-induced circadian disruption: links to initiation of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and risk of hepatic cancer.夜班导致的昼夜节律紊乱：与非酒精性脂肪性肝病/非酒精性脂肪性肝炎的发病及肝癌风险的关联
Hepatoma Res. 2024 Oct 30. doi: 10.20517/2394-5079.2024.88.
4
Accelerometer-derived moderate-to-vigorous physical activity and incident nonalcoholic fatty liver disease.加速度计测量的中等到剧烈身体活动与非酒精性脂肪性肝病发病的关系。
BMC Med. 2024 Sep 18;22(1):398. doi: 10.1186/s12916-024-03618-2.
5
Shift work and evening chronotype are associated with hepatic fat fraction and non-alcoholic fatty liver disease in 282,303 UK biobank participants.在282303名英国生物银行参与者中，轮班工作和晚睡型生物钟与肝脏脂肪分数及非酒精性脂肪性肝病相关。
Endocr Connect. 2024 Jan 12;13(2). doi: 10.1530/EC-23-0472. Print 2024 Feb 1.
6
Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers.非酒精性脂肪性肝病风险与胃肠道癌症的关联。
Hepatol Commun. 2022 Dec;6(12):3299-3310. doi: 10.1002/hep4.2073. Epub 2022 Oct 11.
7
Improving the accuracy of fatty liver index to reflect liver fat content with predictive regression modelling.应用预测回归模型提高脂肪肝指数反映肝内脂肪含量的准确性。
PLoS One. 2022 Sep 13;17(9):e0273171. doi: 10.1371/journal.pone.0273171. eCollection 2022.
本文引用的文献
1
Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease.达拉斯脂肪变性指数可识别非酒精性脂肪性肝病患者。
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2073-2080.e7. doi: 10.1016/j.cgh.2020.01.020. Epub 2020 Jan 23.
2
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.美国 2 型糖尿病患者非酒精性脂肪性肝炎的经济和临床负担
Diabetes Care. 2020 Feb;43(2):283-289. doi: 10.2337/dc19-1113. Epub 2019 Oct 28.
3
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
4
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
5
Characterisation of liver fat in the UK Biobank cohort.英国生物银行队列中肝脏脂肪的特征分析。
PLoS One. 2017 Feb 27;12(2):e0172921. doi: 10.1371/journal.pone.0172921. eCollection 2017.
6
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.肝纤维化而非其他组织学特征与非酒精性脂肪性肝病患者的长期预后相关。
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.
7
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.应用受控衰减参数和肝硬度测量筛查糖尿病患者的非酒精性脂肪性肝病：一项前瞻性队列研究。
Gut. 2016 Aug;65(8):1359-68. doi: 10.1136/gutjnl-2015-309265. Epub 2015 Apr 14.
8
Decision curve analysis: a novel method for evaluating prediction models.决策曲线分析：一种评估预测模型的新方法。
Med Decis Making. 2006 Nov-Dec;26(6):565-74. doi: 10.1177/0272989X06295361.
Zotero 插件